Pharming Group N.V. (NASDAQ: PHAR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 75.49 | EPS (ttm) | 0.15 | Insider Own | 0.01% | Shs Outstand | 70.78M | Perf Week | 8.63% |
| Market Cap | 785.42M | Forward P/E | 41.43 | EPS next Y | 0.26 | Insider Trans | - | Shs Float | 73.29M | Perf Month | -22.01% |
| Enterprise Value | 753.90M | PEG | 0.00 | EPS next Q | 0.11 | Inst Own | - | Short Float | 0.01% | Perf Quarter | -8.75% |
| Income | 9.35M | P/S | 2.14 | EPS this Y | 76.31% | Inst Trans | - | Short Ratio | 1.00 | Perf Half Y | -31.73% |
| Sales | 366.25M | P/B | 3.06 | EPS next Y | 15.31% | ROA | 2.00% | Short Interest | 9.94K | Perf YTD | -38.03% |
| Book/sh | - | P/C | 25.15 | EPS next 5Y | 33.36% | ROE | 3.50% | 52W High | 21.03 -48.69% | Perf Year | -10.90% |
| Cash/sh | - | P/FCF | 25.70 | EPS past 3/5Y | -37.00% -38.91% | ROIC | 2.24% | 52W Low | 9.48 13.83% | Perf 3Y | -7.67% |
| Dividend Est. | - | EV/EBITDA | 21.15 | Sales past 3/5Y | 22.21% 12.14% | Gross Margin | 86.50% | Volatility | 3.44% 4.03% | Perf 5Y | -4.12% |
| Dividend TTM | - | EV/Sales | 2.06 | EPS Y/Y TTM | 172.22% | Oper. Margin | 3.99% | ATR (14) | 0.62 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.31 | Sales Y/Y TTM | 18.83% | Profit Margin | 2.55% | RSI (14) | 36.85 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.01 | EPS Q/Q | -66.67% | SMA20 | -10.10% | Beta | 0.01 | Target Price | 38.00 |
| Payout | 0.00% | Debt/Eq | 0.49 | Sales Q/Q | -3.23% | SMA50 | -14.18% | Rel Volume | 0.65 | Prev Close | 10.95 |
| Employees | 407 | LT Debt/Eq | 0.39 | Earnings | Nov 05 | SMA200 | -28.78% | Avg Volume | 9.86K | Price | 10.79 |
| IPO Date | Dec 23, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -68.25% -9.36% | Net Debt/EBITDA | -0.88 | Volume | 6,391 | Change | -1.45% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-08-26 | Reiterated | Oppenheimer | Outperform | $41 → $40 |
| Apr-10-26 | Initiated | Canaccord on growth potential | Buy | $37 |
| Mar-12-26 | Reiterated | H.C. Wainwright | Buy | $37 |
| Nov-07-25 | Reiterated | Oppenheimer | Outperform | $41 → $42 |
| Dec-09-24 | Reiterated | Jefferies | $14 |
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 366 | 376 | 308 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 50 | 46 | 37 | — | — | — | — | — | — | |
| Gross Profit | 317 | 331 | 271 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 192 | 117 | 103 | — | — | — | — | — | — | |
| Research and Development | 113 | 100 | 86 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 93 | 91 | — | — | — | — | — | — | |
| Operating Income | 13 | 21 | -9 | — | — | — | — | — | — | |
| Interest Expense | 15 | 11 | 9 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 3 | 9 | — | — | — | — | — | — | |
| Net Income Before Taxes | 16 | 13 | -9 | — | — | — | — | — | — | |
| Income Taxes | 6 | 10 | 3 | — | — | — | — | — | — | |
| Consolidated Net Income | 10 | 3 | -12 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 10 | 3 | -12 | — | — | — | — | — | — | |
| Net Income | 10 | 3 | -12 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.14 | 0.04 | -0.18 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.14 | 0.04 | -0.18 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.13 | 0.04 | -0.18 | — | — | — | — | — | — | |
| EBITDA | 42 | 35 | 17 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 83.01 | 441.75 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.06 | 3.34 | 2.26 | — | — | — | — | — | — | |
| Gross Margin | 86.61 | 88.03 | 87.99 | — | — | — | — | — | — | |
| Operating Margin | 3.55 | 5.59 | -2.92 | — | — | — | — | — | — | |
| Net Margin | 2.73 | 0.80 | -3.90 | — | — | — | — | — | — | |
| Shares Outstanding | 70 | 71 | 69 | — | — | — | — | — | — | |
| Market Capitalization | 755 | 1,255 | 695 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |